EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

Company limited by guarantee

Company Registration Number:
06384429 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2021

Period of accounts

Start date: 1 January 2021

End date: 31 December 2021

EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

Contents of the Financial Statements

for the Period Ended 31 December 2021

Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

Balance sheet

As at 31 December 2021

Notes 2021 2020


£

£
Current assets
Cash at bank and in hand: 109,634 5,866
Total current assets: 109,634 5,866
Creditors: amounts falling due within one year: 3 ( 110,053 ) ( 9,162 )
Net current assets (liabilities): (419) (3,296)
Total assets less current liabilities: (419) ( 3,296)
Total net assets (liabilities): (419) (3,296)
Members' funds
Profit and loss account: (419) ( 3,296)
Total members' funds: ( 419) (3,296)

The notes form part of these financial statements

EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

Balance sheet statements

For the year ending 31 December 2021 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 22 August 2022
and signed on behalf of the board by:

Name: Michael Isles
Status: Director

The notes form part of these financial statements

EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

Notes to the Financial Statements

for the Period Ended 31 December 2021

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

Notes to the Financial Statements

for the Period Ended 31 December 2021

  • 2. Employees

    2021 2020
    Average number of employees during the period 2 2

EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

Notes to the Financial Statements

for the Period Ended 31 December 2021

3. Creditors: amounts falling due within one year note

2021 2020
£ £
Other creditors 110,053 9,162
Total 110,053 9,162

COMMUNITY INTEREST ANNUAL REPORT

EUROPEAN ALLIANCE FOR ACCESS TO SAFE MEDICINES COMMUNITY INTEREST COMPANY

Company Number: 06384429 (England and Wales)

Year Ending: 31 December 2021

Company activities and impact

The EAASM is also involved in activities relating to patient safety in the areas of off label use of medicines and compunding of medicines and a contribution was made via a presentation to further this cause and also additional input in to theongoing programme was made to the European Brain Council who are the main coordinators of this GOLUP (Good Off Label Use Practice)The EAASM continues its major medication error and traceability patient safety project with the aim to significantly reduce medication errors by enhancing traceability processes. A scientific committee was further consulted on the generation of the comprehensive survey established along with a growing number of academic and hospital/healthcare organisations. The project has its own website and has just completed a pan EU survey across 13 countries including the private hospital association. The results have contributed to a Call to Action White Paper within the EU institutions - mainly DG Sante. A round table was held in March 22 to publicise the results of the survey and to commence the Call to Action.The EAASM is actively involved with the EU Parliament and attends relevant meetings and hosts healthcare debates in the parliament bringing together MEP's, Commission and the Council.The EAASM also supports the objectives and recommendations for the Pharmaceutical Strategy for Europe with the EU Heathcare Coalition to which it is a partner. it also contributed to the EU Commission Structural Dialogue initiative on product shortages and was an active participant in this new EU consultative approach.The EAASM recalls that the internet is the largest unregulated pharmaceutical market place in the world with 62% of medicines purchased online being falsified or substandard with 95.6% of online pharmacies researched operating illegally. The EAASM calls on the EC and the member states to build on the introduction of the common logo for online pharmacies and to extend it to a European protocol for licencing online pharmacies which could potentially align with the pre-qualifications of the .pharmacy domain suffix which is well governed by the NABP.The EAASM during 2021 continued its strong advocacy work to effect change of legislation so that nanomedicines and nanosimilars should be assessed by an EMA centralised procedure. In this regard EAASM along with the nanomedicines coalition achieved two important amendments in the EU Parliament own inititive report. A number of meetings have been held with DG Sante to raise awareness about this subject which has patient safety implications. A EU parliament round table was achieved and a new nanomedicines coalition website was launched.A July 2021 newsletter was published and is available on the EAASM website and was sent to all members on the mailing list.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
22 August 2022

And signed on behalf of the board by:
Name: Michael Isles
Status: Director